Tango Q3 net loss $22.3M; cash $360M into 2026; TNG348 Fast Track

Tango Therapeutics, Inc.

2023-Q3 EPS reported -$0.78 revenue$31,096,000

Cash, equivalents and marketable securities $359.9M at Sept 30, 2023; runway into 2026.
Net loss $22.3M ($0.23/share) vs $29.1M ($0.33/share) in Q3 2022; net loss $71.0M YTD.
TNG348 (USP1 inhibitor) granted FDA Fast Track for BRCA1/2-mutant cancers; IND cleared; phase 1/2 start expected H1 2024.
TNG908 (PRMT5) dose escalation ongoing; additional clinical data expected in 2024.
Kanishka Pothula appointed to Board; Jannik Andersen promoted to CSO; $80M private placement closed in August 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.98

Tango Therapeutics, Inc. reported financial results for third quarter ended September 30, 2023.

Period: third quarter ended September 30, 2023
Result: reported results

Exact text from the filing

On November 8, 2023, Tango Therapeutics, Inc. (Tango or the Company) issued a press release relating to its results of operations and financial condition for the quarter ended September 30, 2023.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Tango Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-23-060671

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.